Cytori Therapeutics (CYTX)

Business description

Cytori sells the Celution device to harvest and concentrate Adipose-Derived Regenerative Cells (ADCR) at the bedside for autologous cell therapy. Celution is CE marked, approved in China and sold in Japan.

Share price chart

Share chart

Stock data

Market cap.US$76.8m
Last closeUS$0.71
High / Low (52 weeks)US$2.5 / US$0.4
Stock market listingUS
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(38.7931)51.0(69.4)
Relative *(39.5)49.1(72.4)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
Avacta Group AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Cardio3 BioSciences
Carmat Celldex Therapeutics
Cellectis Cerulean
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel Consort Medical
Curis Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech Molecular Partners
MolMed Mologen AG
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics NeoStem
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Tonix Pharmaceuticals Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals UCB
UDG Healthcare uniQure NV
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology

Company news

Oppenheimer Reiterates Outperform on Cytori Therapeutics Inc Following 1Q:15 ...

Tue, 05 May 2015 16:15:02 GMT

Stock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Prices Registered Direct ...

Tue, 05 May 2015 13:30:00 GMT

Correcting The Facts On Cytori Therapeutics (CYTX)

Tue, 14 Apr 2015 17:20:34 GMT

Cytori Therapeutics (CYTX) Stock Spikes Today on Chinese Approval of ...

Mon, 06 Apr 2015 17:15:00 GMT

Cytori Therapeutics Inc (CYTX) is Trading Lower on Unusual Volume for May 05

Tue, 05 May 2015 21:33:19 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2013A 12.2 (32.6) (38.1) (56.2) N/A N/A
2014A 10.1 (34.7) (41.2) (52.5) N/A N/A
2015E N/A N/A N/A N/A N/A N/A
2016E N/A N/A N/A N/A N/A N/A

Last updated on 24/04/2015

Investment summary

Cytori has FDA approval for the pivotal Phase III STAR Trial, enrolling 80 patients with impaired hand function from scleroderma at up to 20 US sites. Enrolment should start in the next few months. This uses ECCS-50: a specific ADRC preparation. This has orphan status in the EU. A 12-month update on the small Scleradec-I trial has been disclosed. Cytori's exclusive Asian licensee, Lorem Vascular, has been granted regulatory clearance for Celution by the CFDA. This triggers a major stock purchase by Lorem for China. FY14 revenues were $7.6m with a loss of $38.5m. End 2014 cash was $14.6m with debt of $25.4m. Edison's forecasts are under review.

Last updated on 06/05/2015

Industry outlook

The $14.1m BARDA thermal burns therapy contract is progressing. A 90-patient US Phase II study in knee osteoarthritis is underway; data are due in H216. Cruciate ligament and knee meniscus indications may be developed. A Japanese urinary incontinence study is part-sponsored. A GMP Celase enzyme used to prepare cells will be available from May.

Last updated on 06/05/2015

Key management

Marc Hendrick, CEO
Tiago Girao, CFO

Company address

3020 Callan Road
San Diago
CA 92121
United States
+1.858.458.0900
View website